The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
In a comparison of the mental health of patients with acne treated with isotretinoin vs oral antibiotics, which treatment group was found to experience more depressive symptoms and psychological distress?
In a comparison of the mental health of patients with acne treated with isotretinoin vs oral antibiotics, which treatment group was found to experience more depressive symptoms and psychological distress?
Climbing the mountain to get to dermatology residency is bone breaking enough, but what about the next apex, even more specialized training such as a Dermatopathology Fellowship?
Climbing the mountain to get to dermatology residency is bone breaking enough, but what about the next apex, even more specialized training such as a Dermatopathology Fellowship?
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
Test your knowledge of treatment escalation in pediatric atopic dermatitis. This clinical quiz explores when topical therapy is no longer sufficient and when to initiate systemic treatment in children.
What proportion of children aged 6 to 11 years with severe atopic dermatitis receiving dupilumab achieved a height increase of at least 5 percentile points after 4 months of treatment?
What proportion of children aged 6 to 11 years with severe atopic dermatitis receiving dupilumab achieved a height increase of at least 5 percentile points after 4 months of treatment?
Evaluate advanced clinical reasoning in targeted treatment selection, unexpected therapeutic responses, and the challenges of precision medicine in inflammatory dermatology.
Evaluate advanced clinical reasoning in targeted treatment selection, unexpected therapeutic responses, and the challenges of precision medicine in inflammatory dermatology.
Challenge your understanding of inflammatory feedback mechanisms, neuronal sensitization, and the complex cellular interactions involved in chronic dermatologic disease.
Challenge your understanding of inflammatory feedback mechanisms, neuronal sensitization, and the complex cellular interactions involved in chronic dermatologic disease.
Test your clinical understanding of inflammatory disease classification, overlapping immune pathways, and the evolving role of type 2 inflammation in dermatology.
Test your clinical understanding of inflammatory disease classification, overlapping immune pathways, and the evolving role of type 2 inflammation in dermatology.
Challenge your understanding of treatment sequencing, biologic failure, JAK inhibitor escalation, and future biomarker-driven approaches in inflammatory dermatology.
Challenge your understanding of treatment sequencing, biologic failure, JAK inhibitor escalation, and future biomarker-driven approaches in inflammatory dermatology.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Evaluate your clinical approach to selecting targeted therapies across multiple type 2 inflammatory skin diseases by integrating disease biology, symptom burden, and treatment sequencing.
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Which of the following best describes the week 12 efficacy findings for povorcitinib in the phase 3 STOP-HS1 and STOP-HS2 trials in patients with moderate-to-severe hidradenitis suppurativa?
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Evaluate your understanding of disease fluctuation, neuroimmune signaling, cytokine biology, and targeted therapeutic strategies in chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Test your understanding of cytokine signaling, mast cell biology, neuroimmune interactions, and the mechanisms that drive chronic spontaneous urticaria.
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
Assess your understanding of biologic therapy in pediatric atopic dermatitis with this expert quiz. Explore practical barriers to treatment, considerations for young children and caregivers, and real-world factors that influence successful...
2. Which of the following is associated with this condition? 
1. This antinuclear antibody (ANA) is most characteristic of:
2. Which of the following is associated with this condition?
